Cancer treatments have been, and continue to be in most cases, based on the organ site where the tumor originates—some treatments are specific for breast cancer, some for lung cancer, and so on. However, rapid advances in genomic sequencing technologies have led to a recent development that deviates from the long-held notion of treating cancers based on the site of origin.Read More
In 2017, electronic cigarettes (e-cigarettes) were the most commonly used tobacco product among high and middle school students. Many public health experts believe that youth use of e-cigarettes has reached an epidemic proportion.
On September 12, 2018, the U.S. Food and Drug Administration (FDA) announced a series of critical and historic enforcement actions related to the sale and marketing of e-cigarettes to kids. This effort included issuing more than 1,300 warning letters and fines to retailers who illegally sold e-cigarette products to minors.Read More
The past month has seen the U.S. Food and Drug Administration (FDA) expand the use of four anticancer therapeutics, providing new treatment options for patients with four types of cancer. On Aug. 16, 2018, the agency approved the immunotherapeutic nivolumab (Opdivo) for treating certain patients with small cell lung cancer and approved the molecularly targeted therapeutic lenvatinib (Lenvima) for treating certain patients with the most common type of liver cancer, hepatocellular carcinoma.Read More
In the midst of the dog days of summer, the U.S. Food and Drug Administration (FDA) has provided good news for the cancer community: It has approved two new anticancer therapeutics for the treatment of four rare types of cancer.Read More
During the early part of summer 2018, the U.S. Food and Drug Administration (FDA) has approved several new anticancer therapeutics and expanded the use of some previously approved anticancer therapeutics to include new types of cancer.Read More
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.Read More
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the treatment of a certain type of thyroid cancer. Specifically, the FDA approved the use of dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for treating patients who have anaplastic thyroid cancer that cannot be removed by surgery or that has metastasized, and that tests positive for a BRAF V600E gene mutation.Read More
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah) to include certain patients with non-Hodgkin lymphoma.
In August 2017, tisagenlecleucel became …
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form …Read More
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include the treatment of certain patients with the most common form of lung cancer—non–small cell lung cancer (NSCLC).Read More